Advertisement

American Journal of Clinical Dermatology

, Volume 14, Issue 6, pp 429–435 | Cite as

Immunotherapy for Acne Vulgaris: Current Status and Future Directions

  • Thierry SimonartEmail author
Leading Article

Abstract

There is a high unmet clinical need for new and better treatments in acne vulgaris. Propionibacterium acnes has a strong proinflammatory activity and targets molecules involved in the innate cutaneous immunity, keratinocytes and sebaceous glands of the pilosebaceous follicle. The role of P. acnes in acne confers legitimacy on the possible benefits of immunization-based approaches, which may represent a solution for limiting the development of antibiotic-resistant P. acnes. Various immunization-based approaches have been developed over the last decades, including killed pathogen-based vaccines, vaccination against cell wall-anchored sialidase, monoclonal antibodies to the Christie, Atkins, Munch-Peterson factor of P. acnes, anti-Toll-like receptors vaccines and natural antimicrobial peptides. This review summarizes the current evidence and explores the challenges to making this a realistic treatment option for the future.

Keywords

Acne Isotretinoin Adapalene Acne Lesion Acne Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

No sources of funding were used to prepare this review.

Conflicts of interest

The author has no conflicts of interest to disclose.

References

  1. 1.
    Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol. 2009;129(9):2136–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Dréno B. Recent data on epidemiology of acne [in French]. Ann Dermatol Venereol. 2010;137(Suppl. 2):S49–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Gonçalves G, Amado J, Matos M, et al. The prevalence of acne among a group of Portuguese medical students. J Eur Acad Dermatol Venereol. 2012;26(4):514–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Perkins AC, Maglione J, Hillebrand GG, et al. Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt). 2012;21(2):223–30.CrossRefGoogle Scholar
  6. 6.
    Golchai J, Khani SH, Heidarzadeh A, et al. Comparison of anxiety and depression in patients with acne vulgaris and healthy individuals. Indian J Dermatol. 2010;55(4):352–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, selfesteem, mood, and psychological disorders. Dermatol Online J. 2011;17(1):1.PubMedGoogle Scholar
  8. 8.
    Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol. 2012;13(6):357–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim J. Acne vaccines: therapeutic option for the treatment of acne vulgaris? J Invest Dermatol. 2008;128:2353–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012;24(4):235–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol. 1975;65(4):382–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Peréz Del Pulgar JI, Rollman O, Török L, Eady EA, Cove JH. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148(3):467–78.PubMedCrossRefGoogle Scholar
  14. 14.
    Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153(2):395–403.PubMedCrossRefGoogle Scholar
  15. 15.
    Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008;158(2):208–16.PubMedGoogle Scholar
  16. 16.
    Bruggemann H, Henne A, Hoster F, et al. The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science. 2004;305:671–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Sato T, Kurihara H, Akimoto N, Noguchi N, Sasatsu M, Ito A. Augmentation of gene expression and production of promatrix metalloproteinase 2 by Propionibacterium acnes-derived factors in hamster sebocytes and dermal fibroblasts: a possible mechanism for acne scarring. Biol Pharm Bull. 2011;34(2):295–9.PubMedCrossRefGoogle Scholar
  18. 18.
    McDowell A, Valanne S, Ramage G, et al. Propionibacterium acnes types I and II represent phylogenetically distinct groups. J Clin Microbiol. 2005;43(1):326–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS One. 2010;5(8):e12277.PubMedCrossRefGoogle Scholar
  20. 20.
    Kwon HH, Yoon JY, Park SY, Suh DH. Analysis of distribution patterns of Propionibacterium acnes phylotypes and Peptostreptococcus species from acne lesions. Br J Dermatol. 2013 Jun 25 (Epub ahead of print).Google Scholar
  21. 21.
    Beylot C, Auffret N, Poli F, Claudel JP, Leccia MT, Del Giudice P, Dreno B. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2013 Aug 1 (Epub ahead of print).Google Scholar
  22. 22.
    Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169(3):1535–41.PubMedGoogle Scholar
  23. 23.
    Sugisaki H, Yamanaka K, Kakeda M, et al. Increased interferon-gamma, interleukin-12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood mononuclear cells from patient with acne vulgaris: host response but not bacterial species is the determinant factor of the disease. J Dermatol Sci. 2009;55(1):47–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakatsuji T, Liu Y-T, Huang C-P, Gallo RL, Huang C-M. Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris. PLoS One. 2008;3:e1551.PubMedCrossRefGoogle Scholar
  25. 25.
    Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, Thiboutot DM. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132(9):2198–205.PubMedCrossRefGoogle Scholar
  26. 26.
    Chronnell CM, Ghali LR, Ali RS, Quinn AG, Holland DB, Bull JJ, Cunliffe WJ, McKay IA, Philpott MP, Müller-Röver S. Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. J Invest Dermatol. 2001;117(5):1120–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, McDowell A, et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 2006;8:2195–205.PubMedCrossRefGoogle Scholar
  28. 28.
    Harder J, Tsuruta D, Murakami M, Kurokawa I. What is the role of antimicrobial peptides (AMP) in acne vulgaris? Exp Dermatol. 2013;22(6):386–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Jarrousse V, Castex-Rizzi N, Khammari A, Charveron M, Dréno B. Modulation of integrins and filaggrin expression by Propionibacterium acnes extracts on keratinocytes. Arch Dermatol Res. 2007;299(9):441–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Isard O, Knol AC, Ariès MF, Nguyen JM, Khammari A, Castex-Rizzi N, Dréno B. Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation. J Invest Dermatol. 2011;131(1):59–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Iinuma K, Sato T, Akimoto N, Noguchi N, Sasatsu M, Nishijima S, Kurokawa I, Ito A. Involvement of Propionibacterium acnes in the augmentation of lipogenesis in hamster sebaceous glands in vivo and in vitro. J Invest Dermatol. 2009;129(9):2113–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Saint-Leger D, Bague A, Cohen E, Chivot M. A possible role for squalene in the pathogenesis of acne I. In vitro study of squalene oxidation. Br J Dermatol. 1986;114:535–42.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakatsuji T, Kao MC, Zhang L, Zouboulis CC, Gallo RL, Huang CM. Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol. 2010;130(4):985–94.PubMedCrossRefGoogle Scholar
  34. 34.
    Jahns AC, Lundskog B, Ganceviciene R, Palmer RH, Golovleva I, Zouboulis CC, McDowell A, Patrick S, Alexeyev OA. An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study. Br J Dermatol. 2012;167(1):50–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Shaheen B, Gonzalez M. Acne sans P. acnes. J Eur Acad Dermatol Venereol. 2013;27(1):1–10.PubMedCrossRefGoogle Scholar
  36. 36.
    McGinley KJ, Webster GF, Leyden JJ. Regional variations of cutaneous propionibacteria. Appl Environ Microbiol. 1978;35:62–6.PubMedGoogle Scholar
  37. 37.
    Leyden JJ, McGinley KJ, Vowels B. Propionibacterium acnes colonization in acne and non-acne. Dematology. 1988;196:55–8.CrossRefGoogle Scholar
  38. 38.
    Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005;38(1):47–55.PubMedCrossRefGoogle Scholar
  39. 39.
    Murata K, Sugita K, Kobayashi M, Kabashima K, Tokura Y. Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J Dermatol Sci. 2006;42(2):91–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Ingham E, Gowland G, Ward RM, Holland KT, Cunliffe WJ. Antibodies to P. acnes and P. acnes exocellular enzymes in the normal population at various ages and in patients with acne vulgaris. Br J Dermatol. 1987;116:805–12.PubMedCrossRefGoogle Scholar
  41. 41.
    Nakatsuji T, Rasochova L, Huang CM. Vaccine therapy for P. acnes-associated diseases. Infect Disord Drug Targets. 2008;8(3):160–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Webster GF, Indrisano JP, Leyden JJ. Antibody titers to Propionibacterium acnes cell wall carbohydrate in nodulocystic acne patients. J Invest Dermatol. 1985;84:496–500.PubMedCrossRefGoogle Scholar
  43. 43.
    Ashbee HR, Muir SR, Cunliffe WJ, Ingham E. IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Br J Dermatol. 1997;136:730–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Holland K, Cunliffe WJ, Roberts C. Acne vulgaris: an investigation into the number of anaerobic diphtheroids and members of the Micrococcaceae in normal and acne skin. Br J Dermatol. 1977;96:623–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Knop J, Ollefs K, Frosch PJ. Anti-P. acnes antibody in comedonal extracts. J Invest Dermatol. 1983;80(1):9–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Vymola F, Buda J, Lochmann O, Pillich J. Successful treatment of acne by immunotherapy. J Hyg Epidemiol Microbiol Immunol. 1970;14:135–8.PubMedGoogle Scholar
  47. 47.
    Goldman L, Michael JG, Riebel S. The immunobiology of acne. A polyvalent propionibacteria vaccine. Cutis. 1979;23:181–4.PubMedGoogle Scholar
  48. 48.
    Rubisz-Brzezińska J, Wilk-Czyz R, Brzezińska-Wcisło L, Kasprowicz A. Clinical evaluation of serious forms of acne treated with autovaccine. Med Dosw Mikrobiol. 1994;46(1–2 Suppl):35–42 (in Polish).Google Scholar
  49. 49.
    Zaluga E. Skin reactions to antigens of Propionibacterium acnes in patients with acne vulgaris treated with autovaccine. Ann Acad Med Stetin. 1998;44:65–85 (in Polish).Google Scholar
  50. 50.
    Hayashi N, Watanabe H, Yasukawa H, Uratsuji H, Kanazawa H, Ishimaru M, Kotera N, Akatsuka M, Kawashima M. Comedolytic effect of topically applied active vitamin D3 analogue on pseudocomedones in the rhino mouse. Br J Dermatol. 2006;155(5):895–901.PubMedCrossRefGoogle Scholar
  51. 51.
    Nakatsuji T, Liu Y-T, Huang C-P, Gallo RL, Huang C-M. Antibodies elicited by inactivated P. acnes–based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol. 2008;128:2451–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Liu PF, Nakatsuji T, Zhu W, Gallo RL, Huang CM. Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine. 2011;29(17):3230–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Rasko DA, Moreira CG, de Li R, Reading NC, Ritchie JM, Waldor MK, et al. Targeting QseC signaling and virulence for antibiotic development. Science. 2008;321(5892):1078–80.PubMedCrossRefGoogle Scholar
  54. 54.
    Nakatsuji T, Tang DC, Zhang L, Gallo RL, Huang CM. Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment. PLoS One. 2011;6(4):e14797.PubMedCrossRefGoogle Scholar
  55. 55.
    Nagy I, Pivarcsi A, Koreck A, Széll M, Urbán E, Kemény L. Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol. 2005;124(5):931–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Rubinchik E, Dugourd D, Algara T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009;34(5):457–61.PubMedCrossRefGoogle Scholar
  57. 57.
    Wang Y, Zhang Z, Chen L, et al. Cathelicidin-BF, a snake cathelicidin-derived antimicrobial peptide, could be an excellent therapeutic agent for acne vulgaris. PLoS One. 2011;6(7):e22120.PubMedCrossRefGoogle Scholar
  58. 58.
    Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9:244–53.PubMedCrossRefGoogle Scholar
  59. 59.
    Kitagawa H, Yamanaka K, Kakeda M, Inada H, Imai Y, Gabazza EC, Kurokawa I, Mizutani H. Propionibacterium acnes vaccination induces regulatory T cells and Th1 immune responses and improves mouse atopic dermatitis. Exp Dermatol. 2011;20(2):157–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.BrusselsBelgium

Personalised recommendations